Compare · GSK vs IQV
GSK vs IQV
Side-by-side comparison of GSK plc (GSK) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GSK focuses on Biotechnology: Pharmaceutical Preparations, while IQV focuses on Biotechnology: Commercial Physical & Biological Resarch.
- GSK is the larger of the two at $104.83B, about 3.9x IQV ($26.59B).
- Over the past year, GSK is up 31.6% and IQV is up 2.3% - GSK leads by 29.4 points.
- GSK has been more active in the news (30 items in the past 4 weeks vs 11 for IQV).
- Both have 25 recent analyst ratings on file.
- Company
- GSK plc
- IQVIA Holdings Inc.
- Price
- $52.47+2.07%
- $158.44+1.14%
- Market cap
- $104.83B
- $26.59B
- 1M return
- -4.91%
- -7.04%
- 1Y return
- +31.62%
- +2.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- 2013
- News (4w)
- 30
- 11
- Recent ratings
- 25
- 25
GSK plc
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest GSK
Latest IQV
- SEC Form 4 filed by Director Stamps Sheila A
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Kaelin William G Jr
- Director Leonard John M was granted 1,571 shares, increasing direct ownership by 10% to 16,946 units (SEC Form 4)
- Director Goggins Colleen A was granted 1,571 shares, increasing direct ownership by 12% to 14,453 units (SEC Form 4)
- Director Danhakl John G was granted 1,571 shares (SEC Form 4)
- SEC Form 4 filed by Director Fasano Jim
- Director Burt Carol was granted 1,571 shares (SEC Form 4)
- SEC Form S-8 filed by IQVIA Holdings Inc.
- SEC Form 8-K filed by IQVIA Holdings Inc.